An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat

This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact t...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Kimberly A., Jones, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778168/
https://www.ncbi.nlm.nih.gov/pubmed/29285707
http://dx.doi.org/10.1007/s12325-017-0655-z
Descripción
Sumario:This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.

Ejemplares similares